Innovative 'Molecular Glue' Offers Hope in Type 2 Diabetes Management
Eindhoven, Friday, 21 March 2025.
Scientists at Eindhoven University have developed a ‘molecular glue’ that protects insulin-producing cells, potentially revolutionizing treatment for type 2 diabetes.
Breakthrough in Cell Protection
In a significant advancement for diabetes treatment, researchers at Eindhoven University of Technology (TU/e) have developed a novel molecular glue that specifically targets and protects insulin-producing beta cells from damage [1]. This innovative research, published in Nature Communications, represents a collaboration between TU/e and the University of Duisburg-Essen, with the research team focusing on preventing cell damage caused by excessive glucose and fats in the blood [1].
How the Technology Works
The molecular glue works by binding to a regulatory protein called ChREBP, which plays a crucial role in glucose processing [1]. PhD candidates Emira Visser and Marloes Pennings, working under the leadership of Professor Luc Brunsveld, designed these specialized molecules to prevent ChREBP hyperactivity, which is a key factor in the development of type 2 diabetes [1]. The research team envisions the treatment being administered in pill form, which would be ‘far less invasive than carrying an insulin pump,’ according to Professor Brunsveld [1].
Future Development Path
The research is currently in a critical phase of development, with the team planning to conduct preclinical testing to evaluate the compound’s potential for clinical use [1]. PhD candidate Marloes Pennings emphasizes that a key focus of the next phase will be assessing the stability of the compound within the body to ensure it maintains its intended function [1]. The project’s scope is set to expand, with future research planned at Mount Sinai in New York [1]. This development comes at a crucial time, as type 2 diabetes continues to be a significant health challenge [GPT].